Payment overview · 2025
General Payments
$1,467.39
50 reported records · 14 companies
Healthcare provider profile · identity verified
Sarat Meka, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, AL · NPI 1952560765
Verified facts
What the public records show
CMS Open Payments records show Sarat Meka, MD received $1,467.39 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $463.92 | 31.6% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.58 | 10.1% | 9 | 2025 |
| Cerapedics Inc. | Unresolved — no canonical attribution shown | $140.34 | 9.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $138.81 | 9.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $121.67 | 8.3% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $120.37 | 8.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.82 | 6.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.45 | 4.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.33 | 4.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.21 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.48 | 1.7% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $23.55 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.42 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.44 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,467.39 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $340.66 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $171.01 | 6 | 2025 |
Source payment records
|
|||||
| I-FACTOR PEPTIDE ENHANCED BONE GRAFT Normalized: i factor peptide enhanced bone graft |
Device | Cerapedics Inc. | $140.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $138.81 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $124.98 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $121.67 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $120.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.03 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.45 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.33 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $57.40 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.59 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.23 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $11.58 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 331 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 224 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
331 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
224 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
225 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 978 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 609 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 565 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 538 | 115 |
| Gabapentin | Gabapentin | 394 | 71 |
| Lisinopril | Lisinopril | 378 | 83 |
| Losartan Potassium | Losartan Potassium | 375 | 87 |
| Furosemide | Furosemide | 367 | 75 |
| Potassium Chloride | Potassium Chloride | 345 | 74 |
| Farxiga | Dapagliflozin Propanediol | 331 | 59 |
| Tramadol Hcl | Tramadol Hcl | 327 | 56 |
| Famotidine | Famotidine | 319 | 69 |
| Eliquis | Apixaban | 282 | 25 |
| Carvedilol | Carvedilol | 276 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 48 |
| Sertraline Hcl | Sertraline Hcl | 246 | 38 |
| Omeprazole | Omeprazole | 240 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 77 |
| Metformin Hcl | Metformin Hcl | 229 | 50 |
| Ozempic | Semaglutide | 225 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 224 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 58 |
| Meloxicam | Meloxicam | 206 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 21 |
| Alprazolam | Alprazolam | 178 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 177 | 11 |
| Trazodone Hcl | Trazodone Hcl | 168 | 37 |
| Simvastatin | Simvastatin | 164 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 44 |
| Donepezil Hcl | Donepezil Hcl | 144 | 15 |
| Levetiracetam | Levetiracetam | 138 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 21 |
| Januvia | Sitagliptin Phosphate | 123 | 13 |
| Mirtazapine | Mirtazapine | 122 | 14 |
| Jardiance | Empagliflozin | 121 | 32 |
| Metformin Hcl Er | Metformin Hcl | 120 | 31 |
| Allopurinol | Allopurinol | 117 | 27 |
| Montelukast Sodium | Montelukast Sodium | 115 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 37 |
| Clonidine Hcl | Clonidine Hcl | 106 | 31 |
| Buspirone Hcl | Buspirone Hcl | 104 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | suppressed |
| Clonazepam | Clonazepam | 95 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | suppressed |
| Memantine Hcl | Memantine Hcl | 88 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 84 | 21 |
| Ondansetron Odt | Ondansetron | 82 | 31 |
| Vascepa | Icosapent Ethyl | 78 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 16 |
| Entresto | Sacubitril/Valsartan | 77 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 76 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | suppressed |
| Torsemide | Torsemide | 74 | 11 |
| Linzess | Linaclotide | 73 | 16 |
| Pregabalin | Pregabalin | 73 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Lorazepam | Lorazepam | 71 | 13 |
| Enalapril Maleate | Enalapril Maleate | 68 | 16 |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Trulicity | Dulaglutide | 63 | suppressed |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 59 | suppressed |
| Indapamide | Indapamide | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 50 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 16 |
| Spironolactone | Spironolactone | 57 | 16 |
| Tradjenta | Linagliptin | 54 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Azelastine Hcl | Azelastine Hcl | 47 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 46 | 11 |
| Mupirocin | Mupirocin | 46 | 26 |
| Atenolol | Atenolol | 45 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 12 |
| Fluconazole | Fluconazole | 31 | 14 |
| Colchicine | Colchicine | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,467.39 · 50 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, I-FACTOR PEPTIDE ENHANCED BONE GRAFT, IBSRELA, INSPIRE, Kerendia, Korlym, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error